11:51 AM
 | 
Apr 25, 2018
 |  BC Extra  |  Clinical News

ADC Therapeutics discontinues HER2 program

ADC Therapeutics S.A. (Épalinges, Switzerland) said it discontinued ADCT-502 after Phase I data of the antibody-drug conjugate (ADC) in patients with HER2-expressing advanced solid tumors did not show "sufficient patient benefit to justify further development."

ADCT-502 comprises an engineered version of trastuzumab, which is a humanized mAb against...

Read the full 218 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >